Lilly USA, LLC
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$248Mgeneral payments (2019-2025)
$3.1Mresearch payments (2019-2025)
242,829clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
- Mounjaro $36M associated (2023-2025)
- Zepbound $20M associated (2023-2025)
- Jardiance $13M associated (2023-2025)
- Ebglyss $12M associated (2023-2025)
- Taltz $9.0M associated (2023-2025)
- Olumiant $7.6M associated (2023-2025)
- Omvoh $6.4M associated (2023-2025)
- Kisunla $5.6M associated (2023-2025)
- Verzenio $3.2M associated (2023-2025)
- Jaypirca $1.9M associated (2023-2025)
- Emgality $1.5M associated (2023-2025)
- Trulicity $749K associated (2023-2025)
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Craig Wierum | Nashville, TN | Endocrinology, Diabetes & Metabolism | $798,937.45 |
| Carlos Campos | New Braunfels, TX | Family Medicine | $753,537.15 |
| Robert Busch | Albany, NY | Endocrinology, Diabetes & Metabolism | $725,879.58 |
| Daniel Nadeau | Newport Beach, CA | Endocrinology, Diabetes & Metabolism | $658,563.94 |
| Lowell Schmeltz | Farmington Hills, MI | Endocrinology, Diabetes & Metabolism | $643,192.04 |
| Ahmad Amin | Naperville, IL | Dermatology | $635,278.31 |
| Eden Miller | Bend, OR | Family Medicine | $634,952.26 |
| Steve Fordan | Dallas, TX | Endocrinology, Diabetes & Metabolism | $633,023.63 |
| Arelis Madera | Port Charlotte, FL | Endocrinology, Diabetes & Metabolism | $632,543.76 |
| Ajay Chaudhuri | Buffalo, NY | Endocrinology, Diabetes & Metabolism | $619,966.55 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.